Cardiorespiratory responses to 6-minute walk test in interstitial lung disease: not always a submaximal test

Anne E Holland, Leona Dowman, Julio Fiore Jr, Danny Brazzale, Catherine J Hill, Christine F McDonald, Anne E Holland, Leona Dowman, Julio Fiore Jr, Danny Brazzale, Catherine J Hill, Christine F McDonald

Abstract

Background: The 6-minute walk test (6 MWT) is used to measure exercise capacity and assess prognosis in interstitial lung disease (ILD). Although the 6 MWT is usually considered to be a test of submaximal exercise capacity in ILD, the physiological load imposed by this test is not well described and 6 MWT outcomes are poorly understood. This study aimed to compare cardiorespiratory responses to 6 MWT and cardiopulmonary exercise test (CPET) in people with ILD.

Methods: 47 participants with ILD (27 idiopathic pulmonary fibrosis (IPF), mean age 71 (SD 12) years, diffusing capacity for carbon monoxide (TLCO) 49(15) %predicted) undertook CPET and 6 MWT on the same day in random order. Oxygen uptake (VO(2)), ventilation (VE) and carbon dioxide production (VCO2) were assessed during each test using a portable metabolic cart.

Results: The VO(2)peak during the 6 MWT was lower than during CPET (1.17(0.27) vs 1.30(0.37) L.min-1, p = 0.001), representing an average of 94% (range 62-135%) of CPET VO(2)peak. Achieving a higher percentage of CPET VO(2)peak on 6 MWT was associated with lower TLCO %predicted (r = -0.43, p = 0.003) and more desaturation during walking (r = -0.46, p = 0.01). The VEpeak and VCO(2)peak were significantly lower during 6 MWT than CPET (p < 0.05). However, participants desaturated more during the 6 MWT (86(6)% vs 89(4)%, p < 0.001). The degree of desaturation was not affected by the percent of peak VO2 achieved during the 6 MWT. Responses were similar in the subgroup with IPF.

Conclusions: On average, the 6 MWT elicits a high but submaximal oxygen uptake in people with ILD. However the physiological load varies between individuals, with higher peak VO2 in those with more severe disease that may match or exceed that achieved on CPET. The 6 MWT is not always a test of submaximal exercise capacity in people with ILD.

Figures

Figure 1
Figure 1
Oxygen uptake (VO2) profile during the six-minute walk test. Data are mean and standard deviation. * represents significant difference compared to previous minute on 6MWT.
Figure 2
Figure 2
Relationship between TLCO%predicted and % of peak VO2 achieved during 6MWT.
Figure 3
Figure 3
Relationship between nadir SpO2 on 6MWT and % of peak VO2 achieved during 6MWT.

References

    1. Holland AE. Exercise limitation in interstitial lung disease - mechanisms, significance and therapeutic options. Chron Respir Dis. 2010;7:101–111.
    1. Eaton T, Young P, Milne D, Wells AU. Six-minute walk, maximal exercise tests: reproducibility in fibrotic interstitial pneumonia. Am J Respir Crit Care Med. 2005;171:1150–1157.
    1. Fell CD, Liu LX, Motika C, Kazerooni EA, Gross BH, Travis WD, Colby TV, Murray S, Toews GB, Martinez FJ, Flaherty KR. The prognostic value of cardiopulmonary exercise testing in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2009;179:402–407.
    1. Kawut SM, O'Shea MK, Bartels MN, Wilt JS, Sonett JR, Arcasoy SM. Exercise testing determines survival in patients with diffuse parenchymal lung disease evaluated for lung transplantation. Respir Med. 2005;99:1431–1439.
    1. Miki K, Maekura R, Hiraga T, Okuda Y, Okamoto T, Hirotani A, Ogura T. Impairments and prognostic factors for survival in patients with idiopathic pulmonary fibrosis. Respir Med. 2003;97:482–490.
    1. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, Colby TV, Cordier JF, Flaherty KR, Lasky JA, Lynch DA, Ryu JH, Swigris JJ, Wells AU, Ancochea J, Bouros D, Carvalho C, Costabel U, Ebina M, Hansell DM, Johkoh T, Kim DS, King TE Jr, Kondoh Y, Myers J, Muller NL, Nicholson AG, Richeldi L, Selman M, Dudden RF. et official ATS/ERS/JRS/ALAT statement: Idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183:788–824.
    1. du Bois RM, Weycker D, Albera C, Bradford WZ, Costabel U, Kartashov A, Lancaster L, Noble PW, Sahn SA, Szwarcberg J, Thomeer M, Valeyre D, King TE Jr. Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference. Am J Respir Crit Care Med. 2011;183:1231–1237.
    1. Lederer DJ, Arcasoy SM, Wilt JS, D'Ovidio F, Sonett JR, Kawut SM. Six-minute-walk distance predicts waiting list survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2006;174:659–664.
    1. Caminati A, Bianchi A, Cassandro R, Mirenda MR, Harari S. Walking distance on 6-MWT is a prognostic factor in idiopathic pulmonary fibrosis. Respir Med. 2009;103:117–123.
    1. Flaherty KR, Andrei AC, Murray S, Fraley C, Colby TV, Travis WD, Lama V, Kazerooni EA, Gross BH, Toews GB, Martinez FJ. Idiopathic pulmonary fibrosis: prognostic value of changes in physiology and six-minute-walk test. Am J Respir Crit Care Med. 2006;174:803–809.
    1. Chetta A, Aiello M, Foresi A, Marangio E, D'Ippolito R, Castagnaro A, Olivieri D. Relationship between outcome measures of six-minute walk test and baseline lung function in patients with interstitial lung disease. Sarcoidosis Vasc Diffuse Lung Dis. 2001;18:170–175.
    1. Garin MC, Highland KB, Silver RM, Strange C. Limitations to the 6-minute walk test in interstitial lung disease and pulmonary hypertension in scleroderma. J Rheumatol. 2009;36:330–336.
    1. Raghu G, Collard HR, Anstrom KJ, Flaherty KR, Fleming TR, King TE Jr, Martinez FJ, Brown KK. Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials. Am J Respir Crit Care Med. 2012;185:1044–1048.
    1. Blanco I, Villaquiran C, Valera JL, Molina-Molina M, Xaubet A, Rodriguez-Roisin R, Barbera JA, Roca J. [Peak oxygen uptake during the six-minute walk test in diffuse interstitial lung disease and pulmonary hypertension] Arch Bronconeumol. 2010;46:122–128.
    1. Hallstrand TS, Boitano LJ, Johnson WC, Spada CA, Hayes JG, Raghu G. The timed walk test as a measure of severity and survival in idiopathic pulmonary fibrosis. Eur Respir J. 2005;25:96–103.
    1. Lama VN, Flaherty KR, Toews GB, Colby TV, Travis WD, Long Q, Murray S, Kazerooni EA, Gross BH, Lynch JP 3rd, Martinez FJ. Prognostic value of desaturation during a 6-minute walk test in idiopathic interstitial pneumonia. Am J Respir Crit Care Med. 2003;168:1084–1090.
    1. Mahler DA, Gifford AH, Waterman LA, Ward J, Machala S, Baird JC. Mechanism of greater oxygen desaturation during walking compared with cycling in patients with COPD. Chest. 2011;140:351–358.
    1. Bradley B, Branley HM, Egan JJ, Greaves MS, Hansell DM, Harrison NK, Hirani N, Hubbard R, Lake F, Millar AB, Wallace WA, Wells AU, Whyte MK, Wilsher ML. Interstitial lung disease guideline: the British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society. Thorax. 2008;63(Suppl 5):v1–v58.
    1. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002;166:111–117.
    1. Benzo RP, Paramesh S, Patel SA, Slivka WA, Sciurba FC. Optimal protocol selection for cardiopulmonary exercise testing in severe COPD. Chest. 2007;132:1500–1505.
    1. Debigare R, Maltais F, Mallet M, Casaburi R, LeBlanc P. Influence of work rate incremental rate on the exercise responses in patients with COPD. Med Sci Sports Exerc. 2000;32:1365–1368.
    1. Holland AE, Knapman L, Brazzale DJ, Conron M, Glaspole I, Goh N, Hill CJ, McDonald CF. The 6-minute walk test elicits high but submaximal cardiorespiratory responses in interstitial lung disease. Respirology. 2010;15:A28.
    1. Hill K, Dolmage TE, Woon L, Coutts D, Goldstein R, Brooks D. Comparing peak and submaximal cardiorespiratory responses during field walking tests with incremental cycle ergometry in COPD. Respirology. 2012;17:278–284.
    1. Luxton N, Alison JA, Wu J, Mackey MG. Relationship between field walking tests and incremental cycle ergometry in COPD. Respirology. 2008;13:856–862.
    1. Troosters T, Vilaro J, Rabinovich R, Casas A, Barbera JA, Rodriguez-Roisin R, Roca J. Physiological responses to the 6-min walk test in patients with chronic obstructive pulmonary disease. Eur Respir J. 2002;20:564–569.
    1. Satake M, Shioya T, Takahashi H, Kawatani M. Ventilatory responses to six-minute walk test, incremental shuttle walking test, and cycle ergometer test in patients with chronic obstructive pulmonary disease. Biomed Res. 2003;24:309–316.
    1. Gay SE, Kazerooni EA, Toews GB, Lynch JP 3rd, Gross BH, Cascade PN, Spizarny DL, Flint A, Schork MA, Whyte RI, Popovich J, Hyzy R, Martinez FJ. Idiopathic pulmonary fibrosis: predicting response to therapy and survival. Am J Respir Crit Care Med. 1998;157:1063–1072.
    1. Shorr AF, Wainright JL, Cors CS, Lettieri CJ, Nathan SD. Pulmonary hypertension in patients with pulmonary fibrosis awaiting lung transplant. Eur Respir J. 2007;30:715–721.

Source: PubMed

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

3
Prenumerera